Seattle Genetics (SGEN) Tops Q4 EPS by 2c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seattle Genetics (SGEN) PT Raised to $77 at H.C. Wainwright
February 7, 2018 7:24 AM ESTH.C. Wainwright raised its price target on Seattle Genetics (NASDAQ: SGEN) to $77.00 (from $75.00) while maintaining a Buy rating.
Analyst Andrew Fein commented, "Beyond ADCETRISs continuous label expansion/revenue growth and the companys ADC platform milestone generation, we see the solid tumor pipeline as the most interesting value driver with three late-stage programs that could expand SGENs footprint beyond hematology. The recent acquisition of Cascadian Therapeutics (CASC; not rated) and its HER2+ breast cancer... More
Seattle Genetics (SGEN) PT Raised to $60 at SunTrust Robinson Humphrey
February 7, 2018 7:10 AM ESTSunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $60.00 (from $52.00) while maintaining a Hold rating.
Analyst Suneja Yatin commented, "SGEN reported a slight (+3%) beat in Adcetris 4Q sales, while LPS also topped Street (-$0.41 vs. -$0.45E) on... More
